NCT00037570已完成2 期
A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer
Wyeth is now a wholly owned subsidiary of Pfizer6 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2000年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 6
研究概览
简要总结
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be men or nonpregnant women at least 18 years of age
- •Patients who present with a gastric or duodenal ulcer (major dimension of the ulcer must be ≥ 5 mm and ≤ 20 mm) with endoscopic appearance of spurting, oozing, or nonbleeding visible vessel (NBVV) Patients presenting with adherent protruding clot are eligible if, after removal of the clot by irrigation, the underlying lesion is classified as spurting, oozing or a NBVV. Patients with an actively bleeding ulcer or a NBVV within a hiatal hernia are eligible if the ulcer is located below the Z-line)
排除标准
- •Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation
- •Patients presenting with active bleeding and/or NBVV at 2 or more separate sites
- •Patients with any severe concomitant diseases, eg, end-stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
2 期
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive DystoniaMovement DisorderDystoniaNCT00331669Charite University, Berlin, Germany24
撤回
1 期
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersMyocardial InfarctionMyocardial IschemiaNCT00743769RegeneRx Biopharmaceuticals, Inc.
Unknown
2 期
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on DialysisDialysisAnemiaChronic Renal FailureNCT02586402Jiangsu Hansoh Pharmaceutical Co., Ltd.60
已完成
4 期
Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver TransplantBone Disease, MetabolicNCT00657852Hospital Clinic of Barcelona79
已完成
2 期
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional TherapyGoutNCT00080210Savient Pharmaceuticals40